Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (826)	6/9/2004 8:46:21 AM
From: tom pope	Read Replies (1) \| Respond to of 2240

Briefing Medarex granted Orphan Drug status for anti-CTLA-4 antibody (MEDX) 2004/06/09 08:01:30 7.10: Co announces that the FDA has granted orphan drug designation to Medarex's fully human anti-CTLA-4 antibody, MDX-010, for the treatment of high risk Stage II, Stage III and Stage IV melanoma. Orphan designation is granted for treatments that offer potential therapeutic value for diseases that affect fewer than 200,000 people in the U.S. Orphan Drug designation also provides eligibility for a special seven-year period of market exclusivity upon approval, potential tax credits for research, grant funding for research and development, reduced filing fees for marketing applications, and assistance with the review of clinical trial protocols.